Due to a more favourable environment, MIMEDX GROUP slightly increases to Slightly Negative
MIMEDX GROUP (US), a company active in the Medical Equipment industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as risky. At the fundamental level, theScreener confirms the rating of 1 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Slightly Negative even if it remains under pressure. As of the analysis date February 11, 2022, the closing price was USD 4.69 and its target price was estimated at USD 2.25.MiMedx Group is a developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human placental tissue, skin and bone. The company's platform include AmnioFix?, EpiFix?, OrthoFlo, Physio?, and CollaFix?. AmnioFix and EpiFix are the company tissues technologies for homologous use processed from human amniotic membrane. OrthoFlo is the company's amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material comprised of 100% bone tissue with no added carrier. CollaFix is designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.